T
Taroh Satoh
Researcher at Osaka University
Publications - 190
Citations - 8238
Taroh Satoh is an academic researcher from Osaka University. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 27, co-authored 190 publications receiving 5705 citations. Previous affiliations of Taroh Satoh include Kindai University.
Papers
More filters
Journal ArticleDOI
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
Narikazu Boku,Taroh Satoh,Min Hee Ryu,Yee Chao,Ken Kato,Hyun Cheol Chung,Jen-Shi Chen,Kei Muro,Won Ki Kang,Kun-Huei Yeh,Takaki Yoshikawa,Sang Cheul Oh,Li Yuan Bai,Takao Tamura,Keun Wook Lee,Yasuo Hamamoto,Jong Gwang Kim,Keisho Chin,Do Youn Oh,Keiko Minashi,Jae Yong Cho,Masahiro Tsuda,Taihei Nishiyama,Li-Tzong Chen,Li-Tzong Chen,Li-Tzong Chen,Yoon-Koo Kang +26 more
TL;DR: In this article, the authors showed that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with ≥ 2 chemotherapy regimens.
Journal ArticleDOI
Quality of Life in the Trastuzumab for Gastric Cancer Trial
Taroh Satoh,Yung-Jue Bang,Evgeny A. Gotovkin,Yasuo Hamamoto,Yoon-Koo Kang,Vladimir Moiseyenko,Atsushi Ohtsu,Eric Van Cutsem,N. Al-Sakaff,Alexa Urspruch,Julie Hill,Harald A. Weber,Hyun Cheol Chung +12 more
TL;DR: Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.
Journal ArticleDOI
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
Taroh Satoh,Yoon-Koo Kang,Yee Chao,Min Hee Ryu,Ken Kato,Hyun Cheol Chung,Jen-Shi Chen,Kei Muro,Won Ki Kang,Kun-Huei Yeh,Takaki Yoshikawa,Sang Cheul Oh,Li Yuan Bai,Takao Tamura,Keun Wook Lee,Yasuo Hamamoto,Jong Gwang Kim,Keisho Chin,Do Youn Oh,Keiko Minashi,Jae Yong Cho,Masahiro Tsuda,Mitsunobu Tanimoto,Li-Tzong Chen,Narikazu Boku +24 more
TL;DR: Nivolumab was efficacious and safe as third- or later-line therapy regardless of prior trastuzumab use in patients with advanced G/GEJ cancer.
Journal Article
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
Toshinori Sueda,Daisuke Sakai,Toshihiro Kudo,Takashi Sugiura,Hidekazu Takahashi,Naotsugu Haraguchi,Junichi Nishimura,Taishi Hata,Taro Hayashi,Tsunekazu Mizushima,Yuichiro Doki,Masaki Mori,Taroh Satoh +12 more
TL;DR: The results showed that regorafenib and TAS-102 have comparable efficacy but different toxicity profiles in patients with mCRC, and both are considered new salvage treatment options.
Journal ArticleDOI
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
Toshihiko Doi,Satoru Iwasa,Kei Muro,Taroh Satoh,Shuichi Hironaka,Taito Esaki,Tomohiro Nishina,Hiroki Hara,Nozomu Machida,Yoshito Komatsu,Yasuhiro Shimada,Satoshi Otsu,Shin Shimizu,Morihiro Watanabe +13 more
TL;DR: Avelumab showed acceptable safety in Japanese patients with advanced solid tumors and clinical activity in patients withadvanced gastric cancer/gastroesophageal junction cancer and disease progression after chemotherapy.